Clovis Oncology Inc. [NASDAQ: CLVS] price surged by 0.86 percent to reach at $0.04. The company report on October 21, 2020 that Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5.
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the company’s results in greater detail.
The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovisoncology.com. A replay of the webcast will be available for 30 days.
A sum of 2031061 shares traded at recent session while its average daily volume was at 4.77M shares. Clovis Oncology Inc. shares reached a high of $5.31 and dropped to a low of $5.10 until finishing in the latest session at $5.28.
The one-year CLVS stock forecast points to a potential upside of 41.33. The average equity rating for CLVS stock is currently 3.30, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Clovis Oncology Inc. [CLVS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLVS shares is $9.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLVS stock is a recommendation set at 3.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 18, 2020. The new note on the price target was released on April 27, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $6, while BofA/Merrill analysts kept a Underperform rating on CLVS stock. On January 08, 2020, analysts decreased their price target for CLVS shares from 36 to 27.
The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.39, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 2.95.
CLVS Stock Performance Analysis:
Clovis Oncology Inc. [CLVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.69. With this latest performance, CLVS shares dropped by -12.28% in over the last four-week period, additionally sinking by -35.47% over the last 6 months – not to mention a rise of 33.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 42.31, with the RSI for the last a single of trading hit 35.84, and the three-weeks RSI is set at 43.01 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 5.81, while it was recorded at 5.44 for the last single week of trading, and 6.95 for the last 200 days.
Insight into Clovis Oncology Inc. Fundamentals:
Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.60 and a Current Ratio set at 2.90.
CLVS Stock EPS
With the latest financial reports released by the company, Clovis Oncology Inc. posted -1.72/share EPS, while the average EPS was predicted by analysts to be reported at -1.89/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clovis Oncology Inc. go to 66.10%.
Clovis Oncology Inc. [CLVS] Insider Position Details
There are presently around $248 million, or 55.30% of CLVS stock, in the hands of institutional investors. The top three institutional holders of CLVS stocks are: STATE STREET CORP with ownership of 9,238,731, which is approximately 151.719% of the company’s market cap and around 0.40% of the total institutional ownership; VANGUARD GROUP INC, holding 6,244,924 shares of the stock with an approximate value of $33.0 million in CLVS stocks shares; and BLACKROCK INC., currently with $29.72 million in CLVS stock with ownership of nearly 48.319% of the company’s market capitalization.
101 institutional holders increased their position in Clovis Oncology Inc. [NASDAQ:CLVS] by around 18,201,214 shares. Additionally, 65 investors decreased positions by around 5,788,510 shares, while 26 investors held positions by with 22,999,420 shares. The mentioned changes placed institutional holdings at 46,989,144 shares, according to the latest SEC report filing. CLVS stock had 38 new institutional investments in for a total of 5,055,798 shares, while 29 institutional investors sold positions of 2,167,118 shares during the same period.